- CONSORT Statement
- CONSORT Statement Extensions
- Evidence underpinning CONSORT
- Accrual and sample size
- Attitudes to trials
- Adverse events (Harms)
- Baseline data
- Blinding
- Compliance
- Early stopping
- Eligibility
- Follow-up
- Funding
- Harms
- Generalizability
- Intention to treat
- Interpretation
- Interventions
- Outcome reporting
- Random allocation
- Recruitment
- Statistical analysis
- Statistical methods
- Trial design issues
- Trial registration
- Uptake of CONSORT by journals
- Impact of and adherence to CONSORT
- Endorsement of CONSORT
Blinding
Birch S. A review and analysis of placebo
treatments, placebo effects, and placebo controls in trials of medical
procedures when sham is not inert. J Altern Complement Med 2006; 12(3):303-310.
PMID: 16646730
Boutron I, Estellat C, Ravaud P. A review of blinding in
randomized controlled trials found results inconsistent and questionable. J
Clin Epidemiol 2005; 58(12):1220-1226.
PMID: 16291465
Boutron I, Estellat C, Guittet L, Dechartres A, Sackett DL,
Hrobjartsson A, Ravaud P. Methods of blinding in reports of randomized
controlled trials assessing pharmacologic treatments: a systematic review. PLoS
Med 2006; 3(10)
PMID: 17076559
Bridgman S, Engebretsen L, Dainty K, Kirkley A, Maffulli N.
Practical aspects of randomization and blinding in randomized clinical trials.
Arthroscopy 2003; 19(9):1000-1006.
PMID: 14608321
Chan AW, Altman DG. Epidemiology and reporting of
randomised trials published in PubMed journals. Lancet 2005;
365(9465):1159-1162.
PMID: 15794971
Cheng K, Smyth RL, Motley J, O'Hea U, Ashby D. Randomized
controlled trials in cystic fibrosis (1966-1997) categorized by time, design,
and intervention. Pediatr Pulmonol 2000; 29(1):1-7.
PMID: 10613779
Clark HD, Wells GA, Huet C, McAlister FA, Salmi LR,
Fergusson D, Laupacis A. Assessing the quality of randomized trials:
reliability of the Jadad scale. Control Clin Trials 1999; 20(5):448-452.
PMID: 10503804
Crow R, Gage H, Hampson S, Hart J, Kimber A, Thomas H. The
role of expectancies in the placebo effect and their use in the delivery of
health care: a systematic review. Health Technol Assess 1999; 3(3):1-96.
PMID: 10448203
Day SJ, Altman DG. Statistics notes: blinding in clinical
trials and other studies. BMJ 2000; 321(7259):504.
PMID: 10948038
Desbiens NA. Lessons learned from attempts to establish the
blind in placebo-controlled trials of zinc for the common cold. Ann Intern Med
2000; 133(4):302-303.
PMID: 10929173
Devereaux PJ, Choi PT, El Dika S, Bhandari M, Montori VM,
Schunemann HJ, Garg AX, Busse JW, Heels-Ansdell D, Ghali WA, Manns BJ, Guyatt
GH. An observational study found that authors of randomized controlled trials
frequently use concealment of randomization and blinding, despite the failure
to report these methods. J Clin Epidemiol 2004; 57(12):1232-1236.
PMID: 15617948
Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C,
Montori VM, Bhandari M, Guyatt GH. Physician interpretations and textbook
definitions of blinding terminology in randomized controlled trials. JAMA 2001;
285(15):2000-2003.
PMID: 11308438
Falagas ME, Pitsouni EI, Bliziotis IA. Trends in the methodological quality of published randomized controlled trials on antibacterial agents. Br J Clin Pharmacol 2008; 65(6):942-954.
PMID: 18279480 [New]
Fergusson D, Glass KC, Waring D, Shapiro S. Turning a blind
eye: the success of blinding reported in a random sample of randomised, placebo
controlled trials. BMJ 2004; 328(7437):432.
PMID: 14761905
Gøtzsche PC. Blinding during data analysis and writing of
manuscripts. Control Clin Trials 1996; 17(4):285-290.
PMID: 8889343
Gøtzsche PC. Methodology and overt and hidden bias in
reports of 196 double-blind trials of nonsteroidal anti-inflammatory drugs in
rheumatoid arthritis. Control Clin Trials 1989; 10(1):31-56.
PMID: 2702836
Hemila H. Allocation concealment and blinding: when
ignorance is bliss. Med J Aust 2005; 183(3):165-166.
PMID: 16175687
Hrobjartsson A, Gøtzsche PC. [What is the effect of placebo
interventions? A systematic review of randomized clinical trials with placebo
treated and untreated patients]. Ugeskr Laeger 2002; 164(3):329-333.
PMID: 11816328
Hrobjartsson A, Forfang E, Haahr M, ls-Nielsen B, Brorson
S. Blinded trials taken to the test: an analysis of randomized clinical trials
that report tests for the success of blinding. Int J Epidemiol 2007;
36(3):654-663.
PMID: 17440024
Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An
analysis of clinical trials comparing placebo with no treatment. N Engl J Med
2001; 344(21):1594-1602.
PMID: 11372012
Hrobjartsson A, Gøtzsche PC. Is the placebo powerless?
Update of a systematic review with 52 new randomized trials comparing placebo
with no treatment. J Intern Med 2004; 256(2):91-100.
PMID: 15257721
Hrobjartsson A, Gøtzsche PC. Placebo interventions for all
clinical conditions. Cochrane Database Syst Rev 2004;(3):CD003974.
PMID: 15266510
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ,
Gavaghan DJ, Mcquay HJ. Assessing the quality of reports of randomized clinical
trials: is blinding necessary? Control Clin Trials 1996; 17(1):1-12.
PMID: 8721797
Kemler MA, de Vet HC. Does randomization introduce bias in
unblinded trials? Epidemiology
2000; 11(2):228.
PMID: 11021625
Kemmler G, Hummer M,
Widschwendter C, Fleischhacker WW. Dropout rates in
placebo-controlled and active-control clinical trials of antipsychotic drugs: a
meta-analysis. Arch Gen Psychiatry 2005; 62(12):1305-1312.
PMID: 16330718
Kjaergard LL, Nikolova D, Gluud C. Randomized clinical
trials in HEPATOLOGY: predictors of quality. Hepatology 1999; 30(5):1134-1138.
PMID: 10534332
Lang T. Masking or blinding? An unscientific survey of
mostly medical journal editors on the great debate. MedGenMed 2000; 2(1):E25.
PMID: 11104471
Lee S, Walker JR, Jakul L, Sexton K. Does elimination of
placebo responders in a placebo run-in increase the treatment effect in
randomized clinical trials? A meta-analytic evaluation. Depress Anxiety 2004;
19(1):10-19.
PMID: 14978780
Montori VM, Bhandari M, Devereaux PJ, Manns BJ, Ghali WA,
Guyatt GH. In the dark: the reporting of blinding status in randomized
controlled trials. J Clin Epidemiol 2002; 55(8):787-790.
PMID: 12384193
Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE,
Yetisir E, Roberts R. The impact of blinding on the results of a randomized,
placebo-controlled multiple sclerosis clinical trial. Neurology 1994;
44(1):16-20.
PMID: 8290055
Poolman RW, Struijs PA, Krips R, Sierevelt IN, Marti RK,
Farrokhyar F, Bhandari M. Reporting of outcomes in orthopaedic randomized
trials: does blinding of outcome assessors matter? J Bone Joint Surg Am 2007;
89(3):550-558.
PMID: 17332104
Quitkin FM, Rabkin JG, Gerald J, Davis JM, Klein DF.
Validity of clinical trials of antidepressants. Am J Psychiatry 2000;
157(3):327-337.
PMID: 10698806
Rees JR, Wade TJ, Levy DA, Colford JM, Jr., Hilton JF.
Changes in beliefs identify unblinding in randomized controlled trials: a
method to meet CONSORT guidelines. Contemp Clin Trials 2005; 26(1):25-37.
PMID: 15837450
Sackett DL. Commentary: Measuring the success of blinding
in RCTs: don't, must, can't or needn't? Int J Epidemiol 2007; 36(3):664-665.
PMID: 17675306
Schulz KF. Assessing allocation concealment and blinding in
randomized controlled trials: why bother? ACP J Club 2000; 132(2):A11-A12.
PMID: 10750446
Schulz KF. Assessing allocation concealment and blinding in
randomised controlled trials: why bother? Evid Based Nurs 2001; 4(1):4-6.
PMID: 11707879
Schulz KF. Assessing allocation concealment and blinding in
randomised controlled trials: why bother? Equine Vet J 2005; 37(5):394-395.
PMID: 16163939
Schulz KF, Grimes DA, Altman DG, Hayes RJ. Blinding and
exclusions after allocation in randomised controlled trials: survey of
published parallel group trials in obstetrics and gynaecology. BMJ 1996;
312(7033):742-744.
PMID: 8605459
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical
evidence of bias. Dimensions of methodological quality associated with
estimates of treatment effects in controlled trials. JAMA 1995; 273(5):408-412.
PMID: 7823387
White AR, Filshie J, Cummings TM. Clinical trials of acupuncture:
consensus recommendations for optimal treatment, sham controls and blinding.
Complement Ther Med 2001; 9(4):237-245.
PMID: 12184353
Page last edited: 06 May 2009
